ABSTRACT Background: Olive oil (OO) consumption is associated with cardiovascular disease prevention because of both its oleic acid and phenolic contents. The capacity of OO phenolics to protect against low-density lipoprotein (LDL) oxidation is the basis for a health claim by the European Food Safety Authority. Proteomic biomarkers enable an early, presymptomatic diagnosis of disease, which makes them important and effective, but understudied, tools for primary prevention. Objective: We evaluated the impact of supplementation with OO, either low or high in phenolics, on urinary proteomic biomarkers of coronary artery disease (CAD), chronic kidney disease (CKD), and diabetes. Design: Self-reported healthy participants (n = 69) were randomly allocated (stratified block random assignment) according to age and body mass index to supplementation with a daily 20-mL dose of OO either low or high in phenolics (18 compared with 286 mg caffeic acid equivalents per kg, respectively) for 6 wk. Urinary proteomic biomarkers were measured at baseline and 3 and 6 wk alongside blood lipids, the antioxidant capacity, and glycation markers. Results: The consumption of both OOs improved the proteomic CAD score at endpoint compared with baseline (mean improvement: -0.3 for low-phenolic OO and 20.2 for high-phenolic OO; P , 0.01) but not CKD or diabetes proteomic biomarkers. However, there was no difference between groups for changes in proteomic biomarkers or any secondary outcomes including plasma triacylglycerols, oxidized LDL, and LDL cholesterol. Conclusion: In comparison with low-phenolic OO, supplementation for 6 wk with high-phenolic OO does not lead to an improvement in cardiovascular health markers in a healthy cohort. This trial was registered at www.controlled-trials.com as ISRCTN93136746.
INTRODUCTION
Olive oil (OO) 5 is the primary source of fat in the Mediterranean diet and is associated with a lower incidence of chronic diseases, particularly cardiovascular diseases (1) (2) (3) . The beneficial effects of OO consumption on cardiovascular disease risk factors were recognized by the Food and Drug Administration and European Food Safety Authority (EFSA) and attributed to the high amounts of MUFAs and phenolic compounds (2, (4) (5) (6) . The EFSA claim, in particular, identified that the daily consumption of 5 mg hydroxytyrosol and derivatives (per 20-g OO dose) could protect LDL particles from oxidative damage if consumed daily (Supplemental Table 1 ) (4).
Phenolic compounds are minor components present in the nonsaponifiable fraction of OO (0.5-1.5% of the oil) along with a great variety of other components, namely hydrocarbons, carotenes, triterpenic compounds, and phytosterols. Health-beneficial properties of phenolic compounds have been attributed to their free-radical scavenging potential (7) and anti-inflammatory properties (3), and more recently, a significant role of these compounds was observed in human in the downregulation of atherosclerosisrelated genes (8) and upregulation of genes involved in cholesterol efflux from cells to HDL (9) , showing their nutrigenomic effects.
Primary outcomes such as total cholesterol, HDL cholesterol, LDL cholesterol, or oxidized LDL have been traditionally used to study the impact of OO consumption on cardiovascular disease risk. These markers are not optimal for nutritional primary prevention because improvement would typically be detected late in the disease progression. A new class of biomarkers, urinary proteomic biomarkers, enables early, presymptomatic detection of disease, which makes them a very important, effective set of tools for primary prevention (10) . Proteomic biomarkers have been used to define specific diseases such as coronary artery disease (CAD), chronic kidney disease (CKD), and diabetes (types 1 and 2) (11, 12) .
A scoring of disease absence, presence, and severity is provided on the basis of the concentration of a group (panel) of urinary peptides measured by capillary electrophoresis coupled with mass spectrometric detection (CE-MS), which allows for the monitoring of progression and effect of treatment (13, 14) . An increase or decrease in the concentration of these peptides determines the scoring value of each disease biomarker. Urinary proteomic biomarkers, although offering a presymptomatic insight on disease-prevention strategies, have yet to be exploited in the context of nutrition and health claims.
The primary aim of this study was to evaluate the impact of a 6-wk supplementation with OOs (20 mL/d) either low or high in phenolics on highly specific urinary proteomic biomarkers of CAD, CKD, and diabetes in healthy adults. To the best of our knowledge, this is the first study to directly report changes in presymptomatic disease status and not on proxies associated with high disease risk (e.g., LDL and oxidized LDL). Secondary outcomes measured included plasma lipids profile, glucose, and fructosamine concentrations as well as total antioxidant status.
SUBJECTS AND METHODS

OO characteristics and methods
OOs with a low-phenolic content (refined OO) and high phenolic content (extra virgin OO), both with similar fatty acid profiles, were supplied by a Portuguese OO producer. An analysis of fatty acids, b sitosterol, free acidity, and peroxide values was carried out according to the European Union regulation for OOs (15) . The phenolic fraction of the oil was extracted by liquidliquid extraction on the basis of the protocol of Owen et al. (16) with modifications. The total phenolic content was assessed spectrophotometrically, and a phenolic composition analysis was carried out by using ultraperformance liquid chromatography (diode array and fluorescence detectors) and liquid chromatographymass spectrometry methodologies (Supplemental Methods 1).
Recruitment
Participants (n = 78) aged 18-75 y were recruited via a poster advertisement in Glasgow, United Kingdom, between August and September 2012. Subjects were (self-reported) healthy adult, with no current diagnosed illness, who were nonregular OO consumers, not pregnant or lactating, and not allergic to olives or olive-derived products. Other exclusion criteria included a history of chronic disease of the gastrointestinal tract, taking any form of medication other than the contraceptive pill, having taken antibiotics in the 3 mo before recruitment, being pregnant, lactating, or trying to conceive. Smokers were not excluded from the study, and there was no restriction related to BMI.
The sample-size calculation (G Power 3.1.5 software; Universitat Dusseldorf) used a comparative case-control follow-up design with the change in coronary artery disease score (DCAD) as a readout variable. The study was powered to detect a difference in the mean DCAD of 0.15 in cases compared with control subjects, assuming a 0.25 (arbitrary units) SD for the DCAD (17) . With the assumption that control subjects would show no changes in the CAD score (DCAD = 0.00) and a 10% dropout rate (consistent with similar nutrition studies), a total of 66 volunteers enabled us to detect a difference between groups (power: 90%; a = 0.05).
The study was approved by the Ethics Committee of the College of Medical, Veterinary & Life Sciences, University of Glasgow (reference 2012071; date: 31 August 2012). Protocols were according to the Declaration of Helsinki, and all participants provided informed consent at recruitment.
Random assignment
The trial followed a randomized, controlled, double-blind parallel design. A total of 78 participants were initially recruited; 9 of these withdrew from the study before random assignment ( Figure 1) . A stratified allocation list was drawn by EC by using block randomization within each stratum (18) according to age (.40 or ,40 y of age) and BMI (in kg/m 2 ; .25 or ,25) with block sizes of n = 6. The allocation sequence was concealed to recruiters (SS and GBC), with intervention assigned over the phone by EC. All investigators in Glasgow and participants were blinded to the sample type (samples A and B).
Study design
Participants were supplied with OO at baseline and midintervention visits. For 6 wk, they consumed a daily dose of 20 mL OO (not heated or cooked) as a supplement (no specific time during the day, single intake, equivalent to 6 mg hydroxytyrosol and derivatives for the high-phenolic OO) in line with EFSA and Food and Drug Administration recommendations. Participants kept food diaries 2 d before the baseline visit and replicated their diet 2 d before days 21 (middle of intervention) and 42 (end of intervention). No dietary restrictions were put in place, and a simple food-frequency questionnaire, based on the European Prospective Investigation into Cancer and Nutrition consortium food-frequency questionnaire (19) , was filled by all participants at recruitment. Compliance was assessed via scrutiny of intake logs alongside the amount of unconsumed oil returned at middle and end visits.
Sample collection
Fasting venous blood was collected at baseline (before ingestion of the first OO dose) and days 21 and 42 in two 12-mL tubes by using EDTA and heparin as an anticoagulant. After centrifugation at 2140 3 g for 5 min at 48C, plasma was split into aliquots and stored at 2808C until analysis. Spot urine samples (second urine of the day) were collected at the same time points, split into aliquots, and frozen at 2208C without any additional additives as recommended (www.eurokup.org) (20) .
Anthropometric measures
Weight was measured to the nearest 100 g by using an electric scale (Seca), height was measured to the nearest millimeter by using a stadiometer (Tanita B.V.), and waist circumference was measured by using a nonelasticated tape at the smallest abdominal OLIVE OIL AND PROTEOMIC BIOMARKERS OF DISEASE position between the lowest rib and iliac crest (with the participant standing after an expiration). Blood pressure was measured by using a digital automatic blood pressure monitor (Omron) with the participant seated after 30 min of rest.
Proteomic analyses by CE-MS
A 0.7-mL aliquot of urine was thawed immediately before use and diluted with 0.7 mL 2 mol urea/L and 10 mmol NH 4 OH/L containing 0.02% sodium dodecyl sulfate as described (21) . The analysis was carried out as previously described (22) and as shown in Supplemental Methods 2. The accuracy, precision, selectivity, sensitivity, reproducibility, and stability of CE-MS measurements were shown elsewhere (21) . Of 189 urine samples available, one sample (from the high-phenolic OO group) was excluded because it did not pass quality-control criteria.
Plasma biomarkers
Commercially available kits were used to determine glucose, triacylglycerols, total cholesterol, and HDL cholesterol (Horiba) by using a semiautomatic analyzer (Cobas Mira Plus; ABX Diagnostics). LDL cholesterol was calculated by using the equation of Friedwald et al. (23) . Oxidized LDL was analyzed by using an ELISA (Promokine). The ferric-reducing ability of plasma was determined as previously reported (23, 24) . Total phenolic content measurements were determined by using the Folin-Ciocalteau method (23, 25) with gallic acid (Sigma Aldrich) as the standard. Samples were analyzed in duplicate with a single analyzer run for each subject. Plasma fructosamine, which is a marker of protein glycation, was analyzed in triplicate as previously described (26) . All CVs (CV percentages) were ,10%.
Statistical analysis
Statistical analyses were performed with SPSS 22.0 software (SPSS Inc.). The normality of variables was assessed by using the Kolmogorov-Smirnoff test. Nonparametric data were log transformed, and values were expressed as antilogarithms. Differences between treatments for each time point were evaluated by using independent t tests and between groups by using a repeatedmeasure ANOVA and post hoc testing with Bonferonni correction (statistical significance: P , 0.05).
The association with the predefined proteomic biomarkers in each sample was assessed on the basis of the concentration of peptides detected calculated from their normalized logarithmic amplitude in the CE-MS analysis. The peptide amplitude between groups was assessed by using Wilcoxon's t test as previously described (27) . All peptides detected in .30% of samples were individually investigated. Correction for multiple testing to ensure a low number of false positives was performed by assessing the false discovery rate as described by Benjamini and Hochberg (23) and previously described for proteomic data sets (27) . A multivariate linear regression analysis was used to describe the effect of selected independent variables on proteomic CAD results (CAD score). The dependent continuous variable was the DCAD at 6 wk with independent variables listed in Table 1 .
RESULTS
OO characterization
The 2 OOs used in the study had a similar fatty acid profile but different phenolic composition ( Table 2 ). The total phenolic content was 18 mg/kg caffeic acid equivalents for the lowphenolic OO compared with 286 mg/kg caffeic acid equivalents for the high-phenolic OO. Hydroxytyrosol and its derivatives were quantified by using liquid chromatography-mass spectrometry for the high-phenolic OO and were 6 mg/20g. Individual phenolic compounds for the high-phenolic OO were p-coumaric acid 0.1%, luteolin 0.8%, vanillin 0.9%, apigenin 1%, tyrosol 4%, hydroxytyrosol 13%, and secoiridoids 80%.
Study cohort
From the 69 participants included and allocated, 63 subjects completed the study (n = 34 for low-phenolic OO and n = 29 for high-phenolic OO), which led to a dropout of 9% ( Figure 1) . No harms or unintended effects were recorded.
Dietary and anthropometric measures
Baseline characteristics of study participants showed no significant differences between groups ( Table 3) . There was a mean increase (P , 0.05) of w5 mm Hg in systolic blood pressure at endpoint for both oils.
No differences were observed for waist-circumference measurements at 3 wk (midpoint) and 6 wk (endpoint) ( Table 4) . There was no difference between groups in term of weight change (as kilograms of body mass or unit of BMI). The weight change was lower than expected for an energy load of 6880 kcal for the intervention on the basis of the energy provided by 20 mL oil (density: 0.91 kg/L, 9 kcal/g, every day for 6 wk), which would have led to an increase in body weight of 0.9 kg over 6 wk.
Proteomic biomarkers
All participants self-reported as healthy. There were no differences between groups at baseline for their proteomic CAD, CKD, or diabetes scores. A subanalysis by sex did not show a difference between groups for these biomarkers. All baseline CAD scores were below the disease threshold of 20.14 (17). Supplementation with both oils led to decreases of 0.3 (low phenolic) and 0.2 (high phenolic) units in the CAD score at endpoint (P , 0.005) ( Table 5 ). There was no difference in CAD at endpoint between the 2 groups. Compiled patterns for urinary proteomic biomarkers were obtained from samples for each trial arm to obtain a typical fingerprint. The proteomic profile monitored comprises all urinary peptides, some of which belong to specific biomarkers studies. The CAD biomarker, for example, is composed of 238 peptides. With the comparison of overall proteomic profiles obtained presupplementation and postsupplementation, 112 peptides changed after low-phenolic OO supplementation, and 133 peptides changed for high-phenolic OO trial arm. Of these peptides, 22 peptides belonged to the 238-peptide CAD biomarker (17) as shown in Table 6 , with 11 peptides changed after low-phenolic OO supplementation, 9 peptides changed after high-phenolic OO supplementation, and 2 peptides changed after supplementation with either oil. The direction of change of identified CAD peptides is presented in Table 6 . Of 11 peptides modified in the high-phenolic group, all of them were increased after the intervention. On the contrary, intake of the oil of low-phenolic content led to mixed effects on the 13 peptides significantly modified in the group. Supplementation with low-or high-phenolic OO did not have a significant effect on proteomic biomarker score for CKD or diabetes (Table 5) .
Plasma biomarkers
There was no significant difference between groups for any of the plasma biomarkers measured. A number of significant changes within groups (between baseline and midpoint or endpoint) were observed (Table 3 and Table 7 ). At midpoint, fasted glucose increased in both low-and high-phenolic OO groups. 1 There were no significant differences between groups. DMF, 1-deoxy-1-morpholino-D-fructose; FRAP, ferric-reducing ability of plasma; GAE, gallic acid equivalent. 2 Mean 6 SD (all such values). 3 For non-normally distributed data, antilogs are presented as means 6 SDs. 4 HDL cholesterol and fasted glucose increased at endpoint in both low-and high-phenolic OO groups. There was no change in either LDL, oxidized LDL, fructosamine, or plasma total phenols within either group. The linear regression model with independent variables listed in Table 1 explained w48% of the variance in DCAD at 6 wk (r = 0.69, r 2 = 0.48, P = 0.001). Age, the phenolic content of OO (high or low), total cholesterol, and LDL cholesterol at baseline were significant predictors (P , 0.05; Table 8 
DISCUSSION
To our knowledge, this work is the first to show that OO supplementation led to a marked improvement in the urinary proteomic biomarker of diseases over a relatively short period in a healthy population. Our results did not show an important contribution of OO phenolics toward a reduction of the CAD score. We could not detect any difference between groups, and the regression analysis only pointed at a small effect size for the phenolic content of OO as a predictor of the DCAD when baseline measurements were accounted for.
The Mediterranean diet, which is characterized by a relative high-fat consumption (mainly from OO), has been linked to reduced risk of cardiovascular mortality (28, 29) along with lower incidence of myocardial infarction in countries from Southern Europe (30) . The United Kingdom population is not a big OO TABLE 5 Changes in scores of CAD, CKD, and diabetes proteomic biomarkers at baseline and middle (3 wk) and end of intervention (6 wk) Values are means 6 SDs; 95% CIs in parentheses. A repeated-measures ANOVA test was used with statistical significance at P , 0.05. * , **Compared with corresponding baseline value: *P , 0.005, **P , 0.001. There were no significant differences in changes between groups. CAD, coronary artery disease; CKD, chronic kidney disease. consumer, and there is a potential for OO, as part of the diet, to improve cardiovascular disease risk factors irrespective of the phenolic content.
In this study, the overall DCAD was qualified as high for both oils with a highly significant change in such a short period of time with the major OO component of fatty acids as the most likely contributors to the effect observed. A previous placebocontrolled intervention with irbesartan (angiotensin II receptor antagonist used for the treatment of hypertension) taken at 300 mg/d over 2 y in hypertensive type 2 diabetes patients by using the same CAD 238 biomarker panel led to a 0.35-point reduction in the CAD score for the drug-controlled group (17) . This decrease was associated with a reduction in the progression to diabetic nephropathy, which is a major vascular complication in diabetes patients. The OO intervention led to a similar change in the biomarker score over a 6-wk period. Our findings, although important, need to be carefully evaluated because an improvement of the biomarker score in a self-reported healthy population does not necessarily translate into a progression toward a healthier status. However, we conclude that OO has a major impact on the CAD biomarker, which warrants addition investigation into its benefits in a less healthy population. This finding also indicates that the CAD biomarker could become a significant tool in nutrition and health intervention studies.
The Mediterranean diet and its components are extensively studied in animal models, generating a hypothesis toward their mechanism of action, such as the interaction between nitrate and fatty acids as an antihypertensive strategy in mice (31) . Although model systems have a place in food and nutrition research, there is a lack of methodologies with strong translational value that would allow investigations of nutritional supplementation in healthy free-living individuals. In this article, we position urinary proteomics as a very valuable tool to achieve this goal, since the methodology was to measure changes in the peptidome as a direct result of disease progression or treatment, accounting for pathophysiologic changes. Eight of the 12 sequenced peptides were significantly regulated toward healthy scoring, including 4 collagen a-1(I) chain, one a-2 (1) chain, onea-2(V) chain, and one a-2(VI) chain fragments. Collagens are the most-abundant peptides sequenced thus far in the CAD biomarker (66% of all peptides) (17) , with atherosclerosis associated with an increased synthesis of several extracellular matrix components, including collagen types I and III, elastin, and several proteoglycans (32) . Changes in circulating concentrations of collagenases may mediate these changes in peptides represented in the fingerprint as reported in coronary atherosclerosis (10, 18) , and CKD (33) .
There was no significant difference between low-and highphenolic OO groups for any of the plasma biomarkers, and differences were seen only within groups (HDL cholesterol and fasted glucose at endpoint for both groups). Increased HDL cholesterol was not detected in the high-compared with lowphenolic OO groups, contrary to the Eurolive study, in which a direct relation between plasma HDL cholesterol and the phenolic content of the OO administered was observed (34) . We also did not observe a difference between groups for oxidized LDL concentrations, again in contrast with the findings of the Eurolive study, in which a linear decrease was observed with the increasing OO phenolic content (34) . The reasons for these differences may be 3-fold and include power, design, and choice of target population. Our study was not powered to detect differences between (or within) groups for plasma biomarkers such as oxidized LDL. With an effect size of 0.17 for changes in Composed of 238 individual peptides. Of 22 peptides listed, only 12 have been sequenced. Arrows indicate the direction of change in urinary peptide concentration. CAD, coronary artery disease; CE, capillary electrophoresis; HPOO, high-phenolic olive oil; LPOO, low-phenolic olive oil.
TABLE 7
Changes in plasma biomarkers at 3 and 6 wk after intervention oxidized LDL between low-and high-phenolic OO groups in the Eurolive study, a total sample of 858 participants for a parallel design (80% power, 1 tail) would be required. An alternative study design could have involved fat replacement, principally to avoid weight gain. However, we adopted a supplementation design to avoid metabolic changes potentially associated with decreased consumption of other fat types. The daily intake of 20 mL OO/d should have led to an extra 6880 kcal ingested over the duration of the study, equivalent to a projected 0.9-kg weight gain. OO consumption is associated with satiation effects (3), which may explain the lower weight gain observed in this study. The lack of significant weight gain in the high-phenolic OO group may have been related to the organoleptic characteristics of the high-phenolic-content OO. Participants provided feedback about the bitter and spicy taste of this OO because of its phenolic content (35) (the low-phenolic OO was characterized as sweet tasting). The taste might have led to lower compliance (not observed via scrutiny of intake logs and returned oil volumes) and also a decrease in other foods consumed by this group (satiation and a reduced desire to eat after intake of the bitter and spicy oil).
Our design was a randomized controlled intervention of supplementation, whereas the Eurolive study had a crossover design in men only, with inherent reduced variability, and OO as fat replacement. In our multiple regression modeling, sex did not predict the DCAD. A subanalysis of our results by sex did not highlight different outcomes for the trial. Our parallel design, which included a broad range of participants in term of ages and body composition with a low dropout rate (,10%), may offer better translational value, because it took in account the variability in the population, which is an important consideration for evidenced-based guideline preparation. A selection of a third, non-OO placebo would have potentially strengthened the design; however, finding an acceptable fat source that could be used in a blinded manner presents additional difficulties (e.g., structure and taste). The use of the general population overcame studydesign limitations previously commented on by the EFSA panel (4) because most human interventions have been conducted in more-homogeneous male populations (4) .
The regression analysis highlighted that some variables may modulate the impact of an OO supplementation in a very low or zero OO consumer population. These variables were age, baseline LDL-cholesterol concentrations, total-cholesterol concentrations, and the phenolic content of the oil. These variables are important to consider during implementation of future OO interventions for the primary prevention of diseases in such populations.
We measured the antioxidant capacity and total phenolic content of plasma and showed no impact of supplementation on these markers consistent with the following facts: 1) these measurements are recognized as nonspecific markers of exposure to highpolyphenol diets, and 2) it is unlikely that dietary supplementation is linked to a direct antioxidant effect (36) .
Protein glycation is relevant to end organ damage, disease pathogenesis, and aging (37) , and olive phenolic compounds have been reported as potent inhibitors of the formation of advanced glycation end products (38) . With glycation occurring in shortlived plasma proteins and longer-lived intracellular proteins such as hemoglobin, a 6-wk (42-d) intervention should have been long enough to detect changes in fructosamine concentrations (39) . Neither low nor high-phenolic OO had a significant impact on plasma fructosamine concentrations, which was indicative of the null or minimal contribution of the supplemented oil phenolics on pathways relevant to protein glycation, including radical scavenging or steric inhibition of protein glycation (40) . This finding may have been due to quantity as much as quality because phenolics are known to exert differential antioxidant and antiglycative activities depending on the structure (1, 38, 41, 42) . Additional minor variations were observed during and after supplementation with both oils, whereby a marginal increase (w0.5 SD, within the normoglycemic range) for fasted glucose concentrations (43) and blood pressure (w5 mm Hg, within the normal blood pressure range, and normal fluctuations for systolic blood pressure of w6 mm Hg (44, 45) . Some of these variations could be attributable to the background lifestyle, rest, and activity level of participants.
In conclusion, to our knowledge, this study is the first to describe the significant impact of daily OO supplementation on highly specific disease biomarkers for CAD, independent of the phenolic content of the oils. Although the study provides additional evidence of the beneficial impact of OO, which is a key ingredient of the Mediterranean diet, on cardiovascular health, it especially offers new perspectives on OO applications. The results, obtained in a broad population group by using a parallel design, are highly translatable for guidelines preparation and nutritional recommendations and will be useful to inform the implementation of large primary-prevention programs in population groups where OO is not a staple.
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